Glow Blend

GHK-Cu: A body of cosmetic and wound-healing research describes GHK-Cu as a tissue-remodeling peptide that increases collagen and elastin and, in controlled studies on aged skin, improves firmness and elasticity and reduces fine lines [PMID:18644225]. In guinea pig wounds GHK-Cu slowed skin reorganization and delayed fibroblast activation; in cultured fibroblasts it lowered proliferation and raised collagen expression [PMID:8836453].

BPC-157: Evidence is mostly preclinical (rodent); human data are limited to small studies, such as a 2-person intravenous safety pilot [PMID:40131143] and an uncontrolled knee-pain chart review [PMID:34324435]. Studies report accelerated tendon, ligament and muscle healing, attributed to angiomodulation and VEGF up-regulation [PMID:20388964][PMID:30915550]. No randomized human efficacy trial has been published in full; one in ulcerative colitis appeared only as a 2005 meeting abstract, and FDA's 2026 review found its data inadequate to support efficacy.

TB-500 / thymosin beta-4: TB-500 is the synthetic active fragment (N-acetyl-LKKTETQ) of thymosin beta-4 [PMID:23084823]. In its unacetylated form, the same seven-residue sequence carries thymosin beta-4's angiogenic, actin-binding activity [PMID:14500546][PMID:38382158], and full-length thymosin beta-4 accelerated dermal healing and reduced inflammation in animal models [PMID:27450738]. A 2016 review by the researchers who first used it in dermal healing also reports faster repair in phase 2 ulcer trials [PMID:27450738], but the published 73-patient venous ulcer trial concluded only that a 0.03% dose "may have the potential to accelerate wound healing" [PMID:20536470]. Those ulcer trials used full-length thymosin beta-4, not TB-500; a 2024 metabolite study states that TB-500's own biological effects have not been documented [PMID:38382158].

Bottom line: the component data are promising but largely preclinical or early-phase, none of it validates the finished blend, and none of these peptides is an approved therapeutic.

Research Use Only - not medical advice. Doses below are stated per component (how much of each is present per injection); the blend itself has never been dosed in a study, so these are community-reported ranges. Beginners typically start at the low end of every component and run a single short cycle.

• GHK-Cu: 1 mg subcutaneous, once daily
• BPC-157: 250 mcg subcutaneous, once daily (often injected near the area of interest in anecdotal use)
• TB-500: 2 mg subcutaneous, twice weekly (loading)

Typical cycle: 4 weeks. Reconstitute with bacteriostatic water, refrigerate after mixing, and rotate injection sites. Start low, assess tolerance, and stop if any adverse reaction appears. See GHK-Cu, BPC-157 and TB-500 for per-component detail. If your only goal is skin appearance, a topical GHK-Cu cosmetic is the lower-risk starting point and avoids injections entirely.

Research Use Only - not medical advice. A standard community cycle after tolerating a beginner run, expressed per component:

• GHK-Cu: 1.5-2 mg subcutaneous, once daily
• BPC-157: 250-500 mcg subcutaneous, once or twice daily
• TB-500: 2-2.5 mg subcutaneous, twice weekly for a 4-6 week loading phase

Typical cycle: ~6 weeks, followed by a 4+ week off period. Many users inject BPC-157 near the recovering tissue and keep GHK-Cu systemic (or switch GHK-Cu to a topical cosmetic formulation for skin-only goals). No data support running this continuously. See BPC-157 and TB-500 for component-level notes.

Research Use Only - not medical advice. Higher exposure carries higher unknown risk and is NOT better supported by evidence. Per component:

• GHK-Cu: 2 mg subcutaneous, once daily
• BPC-157: 500 mcg subcutaneous, twice daily
• TB-500: 2-2.5 mg subcutaneous, twice weekly loading for 4-6 weeks, then a single 2-2.5 mg maintenance dose every 1-2 weeks

Typical structure: 6-8 week loading, then taper to maintenance, then cycle off. Experienced users often keep the three components in separate vials for independent titration rather than a fixed premix, because the ideal ratio for the blend has never been studied. There is no established clinical ceiling for any of these peptides in humans - dosing above component community norms is not evidence-based. See GHK-Cu, BPC-157 and TB-500.